Post-Ozempic patients may eat more calories, Deutsche Bank survey finds

Traders have cheered a brand new class of weight reduction medicine for his or her potential to assist folks shed undesirable kilos, however the findings of a latest ballot underscore the challenges sufferers face in the event that they stop remedy.

The survey by Deutsche Financial institution discovered that calorie consumption declines when a affected person takes a GLP-1 remedy like Novo Nordisk’s Ozempic or Wegovy. Nevertheless, as soon as the remedy is stopped, the variety of energy a affected person consumes will rise once more — and in some instances, will likely be even increased than what she or he was consuming earlier than remedy started, the survey discovered.

The polling was performed in December, and concerned 600 U.S. shoppers, Deutsche Financial institution stated in a analysis notice. Seventy p.c of the contributors have been utilizing a GLP-1 drug when questioned, whereas the remaining 30% had stopped taking this sort of remedy. The funding financial institution performed the survey as a part of its makes an attempt to raised perceive the long-term implications of anti-obesity medicines, which additionally embrace Eli Lilly’s Zepbound, on the meals and beverage business.

The survey discovered that among the many sufferers nonetheless on remedy, about 30% stated they ate “rather less,” whereas 22% stated they ate a “so much much less.”

“Maybe surprisingly, 17% of respondents said that they have been consuming much more and 18% a bit of extra,” the financial institution’s analysts wrote. “This meant {that a} web 18% of those that have been utilizing GLP-1 remedy have been consuming much less.”

“Nevertheless, amongst those that have been not taking GLP-1 this greater than reversed with a web 30% stating that they have been now consuming greater than they have been previous to utilizing GLP-1 remedy,” the report stated.

“We imagine that the survey conclusions again up our view that GLP-1 will not be a cause in of itself to keep away from investing in Meals and Beverage shares,” the analysts wrote within the notice.

Indubitably, 2023 was a 12 months value forgetting for a lot of meals and beverage shares, with many underperforming the market. For these shares that managed to eke out a achieve in 2023, the upside probably got here late within the 12 months.

Many meals and beverage shares started falling in the summertime, as consciousness of GLP-1 medicines like Wegovy unfold. The transfer accelerated after the discharge of information from Novo Nordisk in August confirmed that the medicine might assist sufferers not solely drop some pounds but in addition enhance their cardiovascular well being. Traders began to fret that folks would extensively undertake the medicine and there can be all kinds of ripple results, which began to be mirrored in inventory costs.

However within the midst of the market’s year-end rally, a contemporary batch of information additionally confirmed that sufferers who took Zepbound and stopped regained round half the burden that they had misplaced whereas they have been on the remedy. That discovering helped a number of the affected shares to recuperate.

Shares of Mondelez, the maker of Oreos and Cadbury, gained 16% over the previous three months, which helped it tally an 8% achieve over the previous 12 months. Kraft Heinz shares posted a ten.2% loss over the previous 12 months, however has reaped a 19% achieve over the three-month interval. U.S.-traded shares of Nestle are up greater than 5% over the previous three months, however the inventory has a 2% loss over the previous 12 months. Unilever shares comply with an identical sample. Shares of the Ben & Jerry’s proprietor are up practically 2% over the previous three months, however are down greater than 3% over the previous 12 months.

Deutsche Financial institution stated the affect of anti-obesity medicines on meals and beverage shares must assessed “within the context of all weight reduction applications and the likelihood that GLP-1 cannibalises such applications, limiting the web impact on meals and beverage producers.”

Dr. Shantanu Gaur, founder and CEO of Allurion Applied sciences, stated the outcomes of the survey aren’t stunning. Allurion, which went public by way of SPAC in August, is growing a gastric balloon and habits modification applications to deal with weight problems.

“That is one thing that you’d count on,” he stated explaining that “urge for food can return with a vengeance” as soon as sufferers cease GLP-1 remedy. Our bodies have a tendency to hunt out a “set level,” or a most popular weight mass the place they are going to return to with out intervention and habits modification.

Semaglutide, the energetic ingredient in Ozempic and Wegovy, acts like a pure hormone, glucagon-like peptide-1, or GLP-1, within the physique to manage insulin ranges within the blood and suppress urge for food. Zepbound (tirzepatide) mimics GLP-1 in addition to a second incretin, glucose-dependent insulinotropic polypeptide, or GIP. As soon as these hormones are not supplemented within the physique, starvation alerts will return.

In an e mail, a Novo Nordisk spokesperson stated, “Knowledge from our scientific trials for Wegovy confirmed that, not unexpectedly, sufferers expertise weight regain as soon as they cease taking the remedy. This helps the idea that weight problems is a power illness that requires long-term administration, very like hypertension or excessive ldl cholesterol, for which most sufferers stay on remedy long-term in an effort to proceed to expertise the advantages of their medicines.”

In assertion, an Eli Lilly spokeswoman echoed this remark. “We all know that for some folks residing with weight problems, weight-reduction plan, train and/or behavioral counseling typically fail over the long-term, they usually want extra to realize their weight targets,” she stated.

Nonetheless, even with blood strain remedy, compliance may be a problem. Dr. Gaur stated about half of individuals on ldl cholesterol remedy will cease taking it after a 12 months. The speed of compliance is even decrease with anti-obesity medicines, he stated.

In the meantime, Deutsche Financial institution stated it expects curiosity in weight reduction applications could also be peaking as proven by web search information, and that tends to be a great time for buyers to carry meals and beverage shares. Nestle and Unilever are the agency’s high European picks, whereas Mondelez and Kraft rank amongst its favored U.S. staples names.

“The primary level is that utilization of GLP-1 medicine is not only a pure addition to the full variety of folks on weight reduction applications, it’s a part of the complete eco-system,” the report stated. “We suspect that most of the solutions given with regard to consumption can be comparable for these given by many individuals once they begin a weight reduction program.”

UPDATE: This story was up to date to incorporate a remark from Novo Nordisk and Eli Lilly.

Do not miss these tales from CNBC PRO: